Bionano Genomics Inc. (BNGO)
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Company Description
Bionano Genomics, Inc. provides genome analysis software solutions.
It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight.
The company also provides Saphyr and Bionano compute servers; and NxClinical which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics.
In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; EpiPanelDx PLUS, a genetic testing panel for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures; PGx test, which identifies over 60 alleles in 11 genes.
The company was founded in 2003 and is headquartered in San Diego, California.
Country | United States |
IPO Date | Aug 21, 2018 |
Industry | Medical - Diagnostics & Research |
Sector | Healthcare |
Employees | 344 |
CEO | Dr. Robert Erik Holmlin M.B.A., Ph.D. |
Contact Details
Address: 9540 Towne Centre Drive San Diego, California United States | |
Website | https://www.bionanogenomics.com |
Stock Details
Ticker Symbol | BNGO |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001411690 |
CUSIP Number | 09075F107 |
ISIN Number | US09075F3055 |
Employer ID | 26-1756290 |
SIC Code | 3826 |
Key Executives
Name | Position |
---|---|
Dr. Robert Erik Holmlin M.B.A., Ph.D. | President, Chief Executive Officer & Director and Chief Financial Officer |
Mark Oldakowski | Chief Operating Officer |
Cory Kreeck | Global Head of People Operations |
Donna Polizio | Global Head of Market Access |
Dr. Alka Chaubey FACMG, Ph.D. | Chief Medical Officer |
Jonathan Dixon J.D. | General Counsel & Secretary |
Mark Adamchak CPA | Vice President of Accounting & Controller |
Stanislas Marin M.B.A., M.S. | Vice President of Global Sales |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Jan 27, 2025 | 8-K | Current Report |
Jan 16, 2025 | 8-K | Current Report |
Jan 14, 2025 | 424B3 | Filing |
Jan 13, 2025 | 8-K | Current Report |
Jan 13, 2025 | SCHEDULE 13G | Filing |
Jan 08, 2025 | S-3/A | [Amend] Filing |
Jan 06, 2025 | 8-K | Current Report |
Jan 06, 2025 | 424B5 | Filing |
Jan 03, 2025 | S-3 | Filing |
Jan 03, 2025 | 8-K | Current Report |